{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:47:59Z","timestamp":1782362879393,"version":"3.54.5"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were initially developed as glucose-lowering therapies for type 2 diabetes mellitus. However, large cardiovascular and renal outcome trials have demonstrated rapid reductions in heart failure events and slowing of kidney disease progression, including in patients without diabetes, suggesting benefits beyond glycemic control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To summarize the mechanistic, preclinical, and clinical evidence supporting SGLT2is as acute organ-protective agents and to evaluate their translational potential in time-sensitive clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A structured narrative review was conducted using PubMed, Web of Science, and Embase, focusing on mechanistic studies, experimental acute injury models, randomized controlled trials,\n                      <jats:italic>post hoc<\/jats:italic>\n                      analyses, meta-analyses, and real-world studies published predominantly within the last 5\u20137\u00a0years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SGLT2is may exert acute organ-protective effects through integrated mechanisms involving improved cellular stress adaptation, modulation of ionic and metabolic homeostasis, and hemodynamic as well as immuno-endothelial regulation. Current clinical evidence is most consistent in acute heart failure and early post-myocardial infarction (post-MI) remodeling, whereas evidence in acute kidney injury arrhythmias, stroke, acute lung injury, and liver injury remains limited or exploratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2is should no longer be viewed solely as glucose-lowering agents. Accumulating evidence supports their broader role as potential time-sensitive organ-protective therapies in acute illness, particularly within the cardiorenal spectrum. However, substantial heterogeneity in evidence quality persists, and dedicated acute-care trials are needed to clarify therapeutic timing, patient selection, and safety considerations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1860779","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:21:23Z","timestamp":1782361283000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond glycemic control: SGLT2 inhibitors as time-sensitive organ-protective agents in acute injury\u2014mechanistic insights and translational implications"],"prefix":"10.3389","volume":"17","author":[{"given":"Ji","family":"Wu","sequence":"first","affiliation":[{"name":"Second Clinical Medical College, Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaozheng","family":"Cai","sequence":"additional","affiliation":[{"name":"Second Clinical Medical College, Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Chen","sequence":"additional","affiliation":[{"name":"Second Clinical Medical College, Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, The Second Affiliated Hospital of Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hospital Infection Management, The Second Affiliated Hospital of Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, The Second Affiliated Hospital of Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e10783","DOI":"10.7759\/cureus.10783","article-title":"Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors: benefits in diabetics with cardiovascular disease","volume":"12","author":"Aftab","year":"2020","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1016\/j.clinthera.2020.09.008","article-title":"Potential therapeutic effects of sodium glucose-linked cotransporter 2 inhibitors in stroke","volume":"42","author":"Al Hamed","year":"2020","journal-title":"Clin. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s13300-021-01092-0","article-title":"Safety of dapagliflozin in patients with type 2 diabetes mellitus in Saudi Arabia: a post authorization safety study","volume":"12","author":"Alguwaihes","year":"2021","journal-title":"Diabetes Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s13300-020-00885-z","article-title":"Effect of sodium-glucose Cotransporter-2 inhibitors on endothelial function: a systematic review of preclinical studies","volume":"11","author":"Alshnbari","year":"2020","journal-title":"Diabetes Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr. Diab Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1161\/circulationaha.123.065517","article-title":"Metabolic communication by SGLT2 inhibition","volume":"149","author":"Billing","year":"2024","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/s0140-6736(22)01485-4","article-title":"Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes","volume":"400","author":"Bos","year":"2022","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.3390\/jcm15062260","article-title":"SGLT2 inhibitors after myocardial infarction: evidence, mechanisms and gaps in knowledge","volume":"15","author":"Buonpane","year":"2026","journal-title":"J. Clin. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2337\/dc20-0941","article-title":"Issues of cardiovascular risk management in people with diabetes in the COVID-19 era","volume":"43","author":"Ceriello","year":"2020","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9761","DOI":"10.1038\/s41598-024-60133-3","article-title":"SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea","volume":"14","author":"Cho","year":"2024","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur. Heart J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40264-022-01262-4","article-title":"Post-authorization safety studies of acute liver injury and severe complications of urinary tract infection in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting","volume":"46","author":"Danysh","year":"2023","journal-title":"Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"8786","DOI":"10.3390\/ijms22168786","article-title":"Effects of sodium-glucose Co-Transporter 2 inhibitors on vascular cell function and arterial remodeling","volume":"22","author":"Durante","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e46243","DOI":"10.7759\/cureus.46243","article-title":"Exploring the cardiovascular benefits of sodium-glucose Cotransporter-2 (SGLT2) inhibitors: expanding Horizons beyond diabetes management","volume":"15","author":"Fatima","year":"2023","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/cm9.0000000000003919","article-title":"Obesity and emerging intervention strategies: mechanistic insights and novel drug targets","volume":"139","author":"Feng","year":"2025","journal-title":"Chin. Med. J. Engl."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072030","article-title":"Exploring sodium glucose Co-Transporter-2 (SGLT2) inhibitors for organ protection in COVID-19","volume":"9","author":"Fernandez-Fernandez","year":"2020","journal-title":"J. Clin. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12933-024-02309-9","article-title":"Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial","volume":"23","author":"Fujiki","year":"2024","journal-title":"Cardiovasc Diabetol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12933-020-01163-9","article-title":"Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk","volume":"19","author":"Giorgino","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3390\/life13041024","article-title":"Anti-diabetic therapy and heart failure: recent advances in clinical evidence and molecular mechanism","volume":"13","author":"Hsu","year":"2023","journal-title":"Life (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.34067\/kid.0000000792","article-title":"Effects of sodium-glucose Cotransporter-2 inhibitors on modulating protein-bound uremic toxins and gut microbiota in predialysis CKD patients: matched case-control study","volume":"6","author":"Hsu","year":"2025","journal-title":"Kidney360"},{"key":"B23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-023-01816-5","article-title":"Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms","volume":"22","author":"Huang","year":"2023","journal-title":"Cardiovasc Diabetol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s13238-020-00809-4","article-title":"Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis","volume":"13","author":"Jiang","year":"2022","journal-title":"Protein Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13340-020-00444-8","article-title":"Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches","volume":"11","author":"Kitada","year":"2020","journal-title":"Diabetol. Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.3390\/ijms23031678","article-title":"SGLT2 inhibitors and their antiarrhythmic properties","volume":"23","author":"Kolesnik","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3390\/nu15102294","article-title":"SGLT-2 inhibitors and the inflammasome: what's next in the 21st century?","volume":"15","author":"Kounatidis","year":"2023","journal-title":"Nutrients"},{"key":"B28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","article-title":"Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury","volume":"19","author":"Lahnwong","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.ekir.2024.02.1435","article-title":"Narrative review of immunomodulatory and anti-inflammatory effects of sodium-glucose cotransporter 2 inhibitors: unveiling novel therapeutic frontiers","volume":"9","author":"Lee","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3760\/cma.j.cn115791-20240730-00394","article-title":"Pharmacological mechanism and clinical application prospects of sodium-glucose cotransporter 2 inhibitors","volume":"16","author":"Li","year":"2024","journal-title":"Chin. J. Diabetes Mellitus"},{"key":"B31","doi-asserted-by":"publisher","first-page":"966708","DOI":"10.3389\/fcvm.2022.966708","article-title":"Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: a population-based cohort study","volume":"9","author":"Lin","year":"2022","journal-title":"Front. Cardiovasc Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamacardio.2020.1286","article-title":"Potential effects of coronaviruses on the cardiovascular system: a review","volume":"5","author":"Madjid","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.3390\/jcm14186348","article-title":"Beyond the cardio-renal-metabolic axis: emerging therapeutic targets and novel mechanisms of action of flozins","volume":"14","author":"Matuszewski","year":"2025","journal-title":"J. Clin. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.3390\/ijms26125753","article-title":"The SGLT2 inhibitor empagliflozin mitigates the harmful effects of Methylglyoxal exposure on ovalbumin-induced mouse airway inflammation","volume":"26","author":"Medeiros","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"sfaf350","DOI":"10.1093\/ckj\/sfaf350","article-title":"SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art","volume":"19","author":"Minutolo","year":"2026","journal-title":"Clin. Kidney J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1210\/clinem\/dgad113","article-title":"SGLT2 inhibitors: effect on myocardial infarction and stroke in type 2 diabetes","volume":"108","author":"Mukhopadhyay","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1161\/circulationaha.122.057364","article-title":"Empagliflozin inhibits cardiac late sodium current by Ca\/Calmodulin-dependent kinase II","volume":"146","author":"Mustroph","year":"2022","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e62978","DOI":"10.7759\/cureus.62978","article-title":"Assessing the effect of sodium-glucose cotransporter 2 inhibitor (SGLT2i) on outcomes in patients with acute myocardial infarction: a systematic review and meta-analysis","volume":"16","author":"Nall","year":"2024","journal-title":"Cureus"},{"key":"B39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.33963\/kp.15666","article-title":"Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats","volume":"79","author":"\u00d6zg\u00fcr","year":"2021","journal-title":"Kardiol. Pol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/circulationaha.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/j.jacc.2024.07.013","article-title":"Reaffirmation of mechanistic proteomic signatures accompanying SGLT2 inhibition in patients with heart failure: a validation cohort of the EMPEROR program","volume":"84","author":"Packer","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1111\/dom.14359","article-title":"Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: implications for the COVID-19 pandemic","volume":"23","author":"Patoulias","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/dom.15429","article-title":"Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: post-authorization safety study based on multinational cohorts","volume":"26","author":"Rebordosa","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e015298","DOI":"10.1161\/circimaging.123.015298","article-title":"Cardioprotective effect of empagliflozin and circulating ketone bodies during acute myocardial infarction","volume":"16","author":"Santos-Gallego","year":"2023","journal-title":"Circ. Cardiovasc Imaging"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1159953","DOI":"10.3389\/fcvm.2023.1159953","article-title":"Potential favorable action of sodium-glucose cotransporter-2 inhibitors on sudden cardiac death: a brief overview","volume":"10","author":"Sato","year":"2023","journal-title":"Front. Cardiovasc Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1008922","DOI":"10.3389\/fcvm.2022.1008922","article-title":"Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials","volume":"9","author":"Scisciola","year":"2022","journal-title":"Front. Cardiovasc Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1016\/j.ekir.2025.06.036","article-title":"The protective effects of SGLT-2 inhibitors against postoperative acute kidney injury in type 2 diabetes","volume":"10","author":"Song","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"100021","DOI":"10.1016\/j.aicoj.2025.100021","article-title":"Association between gliflozins use and outcomes in adults with sepsis: a multicenter retrospective cohort study among veterans","volume":"16","author":"Tang","year":"2026","journal-title":"Ann. Intensive Care"},{"key":"B50","doi-asserted-by":"publisher","first-page":"15364","DOI":"10.1038\/s41598-021-94945-4","article-title":"Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Tsai","year":"2021","journal-title":"Sci. Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/s0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/s0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"Von","year":"2022","journal-title":"Eur. Heart J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ahj.2022.01.008","article-title":"Ertugliflozin to reduce arrhythmic burden in ICD\/CRT patients (ERASe-trial) - a phase III study","volume":"246","author":"Von Lewinski","year":"2022","journal-title":"Am. Heart J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.xkme.2019.12.006","article-title":"SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report","volume":"2","author":"Wang","year":"2020","journal-title":"Kidney Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"102262","DOI":"10.1016\/j.redox.2022.102262","article-title":"ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury","volume":"51","author":"Wang","year":"2022","journal-title":"Redox Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1535673","DOI":"10.3389\/fmed.2025.1535673","article-title":"Role of the endothelial cell glycocalyx in sepsis-induced acute kidney injury","volume":"12","author":"Wang","year":"2025","journal-title":"Front. Med. (Lausanne)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"102131","DOI":"10.1016\/j.redox.2021.102131","article-title":"Fibroblast growth factor 21 attenuates iron overload-induced liver injury and fibrosis by inhibiting ferroptosis","volume":"46","author":"Wu","year":"2021","journal-title":"Redox Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1552539","DOI":"10.3389\/fmed.2025.1552539","article-title":"Effect of sodium-glucose co-transporter 2 inhibitor on contrast-induced acute kidney injury and prognosis in type 2 diabetes patients undergoing percutaneous coronary intervention","volume":"12","author":"Yang","year":"2025","journal-title":"Front. Med. (Lausanne)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e007684","DOI":"10.1161\/circheartfailure.120.007684","article-title":"Ketone ester treatment improves cardiac function and reduces pathologic remodeling in preclinical models of heart failure","volume":"14","author":"Yurista","year":"2021","journal-title":"Circ. Heart Fail"},{"key":"B62","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/s0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur. Heart J."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e0317295","DOI":"10.1371\/journal.pone.0317295","article-title":"Dapagliflozin inhibits ferroptosis to improve chronic heart failure by regulating Nrf2\/HO-1\/GPX4 signaling pathway","volume":"20","author":"Zhang","year":"2025","journal-title":"PLoS One"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e22423","DOI":"10.1016\/j.heliyon.2023.e22423","article-title":"Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats","volume":"9","author":"Zhong","year":"2023","journal-title":"Heliyon"},{"key":"B66","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/jcdd10120478","article-title":"SGLT2 inhibitors in long COVID syndrome: is there a potential role?","volume":"10","author":"Zimmermann","year":"2023","journal-title":"J. Cardiovasc Dev. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1860779\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:21:25Z","timestamp":1782361285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1860779\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":66,"alternative-id":["10.3389\/fphar.2026.1860779"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1860779","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"article-number":"1860779"}}